Vanda Pharmaceuticals Inc (VNDA.OQ)
20 Jul 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|65||2014||Independent Chairman of the Board|
|57||2010||President, Chief Executive Officer, Director|
|51||2017||Chief Financial Officer, Executive Vice President, Treasurer|
|51||2016||Senior Vice President, Chief Compliance Officer|
|48||2017||Senior Vice President - Business Development|
- BRIEF-Vanda Pharmaceuticals Says Hetlioz Is Effective In Treating Jet Lag During Transatlantic Travel
- BRIEF-Vanda Pharmaceuticals Inc Reports Qtrly EPS Of $0.06
- Patent on Vanda schizophrenia drug upheld by appeals court
- BRIEF-Vanda Pharmaceuticals Wins Appeal Case On Fanapt
- BRIEF-Vanda Pharmaceuticals Gets Paragraph IV Certification Notice For Generic Version Of Hetlioz Capsule